Fintel reports that on December 23, 2024, HC Wainwright & Co. initiated coverage of Sanara MedTech (NasdaqCM:SMTI) with a Buy recommendation.
Analyst Price Forecast Suggests 33.25% Upside
As of December 23, 2024, the average one-year price target for Sanara MedTech is $44.88/share. The forecasts range from a low of $44.44 to a high of $46.20. The average price target represents an increase of 33.25% from its latest reported closing price of $33.68 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Sanara MedTech is 123MM, an increase of 57.45%. The projected annual non-GAAP EPS is 0.36.
What is the Fund Sentiment?
There are 129 funds or institutions reporting positions in Sanara MedTech. This is an increase of 11 owner(s) or 9.32% in the last quarter. Average portfolio weight of all funds dedicated to SMTI is 0.00%, an increase of 26.28%. Total shares owned by institutions increased in the last three months by 12.14% to 1,010K shares.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 96K shares representing 1.09% ownership of the company. In its prior filing, the firm reported owning 72K shares , representing an increase of 24.93%. The firm increased its portfolio allocation in SMTI by 34.07% over the last quarter.
IWM - iShares Russell 2000 ETF holds 96K shares representing 1.09% ownership of the company. In its prior filing, the firm reported owning 90K shares , representing an increase of 6.04%. The firm decreased its portfolio allocation in SMTI by 1.61% over the last quarter.
Geode Capital Management holds 88K shares representing 1.01% ownership of the company. In its prior filing, the firm reported owning 85K shares , representing an increase of 4.25%. The firm decreased its portfolio allocation in SMTI by 45.91% over the last quarter.
FSSNX - Fidelity Small Cap Index Fund holds 42K shares representing 0.48% ownership of the company. In its prior filing, the firm reported owning 38K shares , representing an increase of 9.78%. The firm decreased its portfolio allocation in SMTI by 3.84% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 41K shares representing 0.47% ownership of the company. No change in the last quarter.
Sanara MedTech Background Information
(This description is provided by the company.)
With a focus on improving patient outcomes through evidence-based healing solutions and services, Sanara MedTech Inc. markets and distributes wound and skin care products and is seeking to offer wound care and dermatology virtual consultation services via telemedicine to physicians, hospitals, clinics, and all post-acute care settings. Sanara's products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX® Surgical Activated Collagen® to the surgical markets as well as the following products to the wound care market: BIAKŌS™ Antimicrobial Skin and Wound Cleanser, BIAKŌS™ Antimicrobial Wound Gel, BIAKŌS™ Antimicrobial Skin and Wound Irrigation Solution, and HYCOL™ Hydrolyzed Collagen Powder and Gel. The company is constantly seeking long-term strategic partnerships with a focus on products and technologies that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its six focus areas of wound and skin care for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal, hydrolyzed collagen, advanced biologics, negative pressure wound therapy adjunct products, and the oxygen delivery system segment of the healthcare industry.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
